James Hay, CFA, is a seasoned professional in the field of investment banking and M&A advisory, currently working in Healthcare Investment Banking at Lazard since September 2018. Prior to this role, James served as Assistant Director for Life Sciences M&A Advisory at Deloitte from March 2015 to September 2018. James began his career as an Assistant Director and Equity Analyst at RBC Brewin Dolphin from June 2010 to January 2015, focusing on the pharmaceutical and biotechnology sectors and covering large- and mid-cap equities across Europe, with notable companies such as Roche, Novartis, and AstraZeneca. James holds a Bachelor of Science (BSc) degree in Medicinal Biology & Genomics from the University of St Andrews.
This person is not in any teams
This person is not in any offices